Search

Displaying results 891 - 900 of 7499 in total
  1. Drug

    Ozenoxacin

    go.drugbank.com/drugs/DB12924
    Approved

    s Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by *Staphylococccus aureus* or *Streptococcus pyogenes* in adult and pediatric patients 2 months of age … Despite being a common and highly contagious bacerial skin infection that affects millions of children and adults in the United States each year, ozenoxacin cream is a novel, non-fluorinated quinolone

  2. Drug

    Peramivir

    go.drugbank.com/drugs/DB06614
    ApprovedInvestigational

    for no more than two days. … Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B.

  3. Drug

    Calcium polycarbophil

    go.drugbank.com/drugs/DB14684
    Approved

    Less gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali. … is physiologically inert, and does not cause gastrointestinal irritation.

    Products: Fiber-ON-tablet
  4. Drug

    Azacitidine

    go.drugbank.com/drugs/DB00928
    ApprovedInvestigational

    myeloid leukemia (AML), two types of cancer characterized by the presence of aberrant DNA methylation. … [A1415] The use of oral azacitidine for the treatment of AML in patients in complete remission was approved by the FDA in September 2020.[L35335]

  5. Drug

    Pectin

    go.drugbank.com/drugs/DB11158
    ApprovedInvestigationalVet approved

    This status allows pectin to be used with no limitations.[L1960]

    Mixtures: NEO ASTA, NEO DIAFORM
  6. Drug

    Nelarabine

    go.drugbank.com/drugs/DB01280
    ApprovedInvestigational

    [A258719] Nelarabine was first granted accelerated approval by the FDA on October 28, 2005, and was manufactured under the trademark name ARRANON by GlaxoSmithKline. … [A2332] Due to the rarity of these T-cell malignancies, nelarabine was first granted orphan drug status and a fast-track designation by the FDA to address the unmet therapeutic needs of these cancers.

  7. Drug

    Melphalan

    go.drugbank.com/drugs/DB01042
    ApprovedInvestigational

    [L40928] It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. … [L47890] It is also used to treat uveal melanoma with unresectable hepatic metastases.[L47895]

    Synonyms: p-N,N-bis(2-chloroethyl)amino-L-phenylalanine, p-N-Bis(2-chloroethyl)amino-L-phenylalanine
  8. Drug

    Trastuzumab deruxtecan

    go.drugbank.com/drugs/DB14962
    ApprovedInvestigational

    [A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.[L10842] … The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class.

  9. Drug

    Neostigmine

    go.drugbank.com/drugs/DB01400
    ApprovedInvestigationalVet approved

    Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. … A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine.

    Synonyms: 3-Trimethylammoniumphenyl N,N-dimethylcarbamate
  10. Drug

    Pimecrolimus

    go.drugbank.com/drugs/DB00337
    ApprovedInvestigational

    Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007.

    Categories: Analgesics, Non-Narcotic